Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its price target hoisted by research analysts at Guggenheim from $800.00 to $1,050.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s target price suggests a potential upside of 220.00% from the stock’s previous close.
PRAX has been the subject of a number of other research reports. Robert W. Baird raised their target price on Praxis Precision Medicines from $514.00 to $568.00 and gave the company an “outperform” rating in a report on Monday. Needham & Company LLC reaffirmed a “buy” rating and set a $582.00 price target on shares of Praxis Precision Medicines in a research note on Thursday, September 24th. The Goldman Sachs Group reiterated a “buy” rating and issued a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Raymond James Financial restated a “strong-buy” rating and set a $945.00 target price on shares of Praxis Precision Medicines in a research report on Monday, August 17th. Finally, Wedbush increased their target price on shares of Praxis Precision Medicines from $188.00 to $189.00 and gave the company an “underperform” rating in a report on Tuesday, November 10th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $647.68.
View Our Latest Analysis on Praxis Precision Medicines
Praxis Precision Medicines Stock Performance
NASDAQ PRAX opened at $328.13 on Monday. The business’s 50 day moving average is $289.90 and its two-hundred day moving average is $314.38. Praxis Precision Medicines has a 12-month low of $160.11 and a 12-month high of $392.70. The stock has a market capitalization of $9.17 billion, a price-to-earnings ratio of -25.64 and a beta of 2.85.
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.54) by $0.31. Equities analysts forecast that Praxis Precision Medicines will post -13.93 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Praxis Precision Medicines
Several hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its holdings in Praxis Precision Medicines by 6.8% during the 1st quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company’s stock valued at $1,113,514,000 after buying an additional 218,777 shares during the last quarter. Perceptive Advisors LLC boosted its stake in shares of Praxis Precision Medicines by 2.0% during the first quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company’s stock valued at $655,974,000 after acquiring an additional 40,000 shares during the last quarter. Bank of America Corp DE increased its position in Praxis Precision Medicines by 2.3% during the 1st quarter. Bank of America Corp DE now owns 534,604 shares of the company’s stock worth $172,244,000 after purchasing an additional 11,841 shares in the last quarter. Vivo Capital LLC increased its position in Praxis Precision Medicines by 3.0% during the 1st quarter. Vivo Capital LLC now owns 338,895 shares of the company’s stock worth $109,189,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Marshall Wace LLP increased its position in Praxis Precision Medicines by 61.7% during the 3rd quarter. Marshall Wace LLP now owns 221,602 shares of the company’s stock worth $64,537,000 after purchasing an additional 84,594 shares in the last quarter. 67.84% of the stock is currently owned by hedge funds and other institutional investors.
About Praxis Precision Medicines
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
See Also
- Five stocks we like better than Praxis Precision Medicines
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
